当前位置: 首页 >> 检索结果
561. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.
作者: Deborah M Friedman.;Mimi Kim.;Nathalie Costedoat-Chalumeau.;Robert Clancy.;Joshua Copel.;Colin K Phoon.;Bettina F Cuneo.;Rebecca Cohen.;Mala Masson.;Benjamin J Wainwright.;Noel Zahr.;Amit Saxena.;Peter M Izmirly.;Jill P Buyon.
来源: Circ Arrhythm Electrophysiol. 2020年13卷10期e008686页
Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine is being considered as prophylaxis and treatment of coronavirus disease-19 (COVID-19). Although hydroxychloroquine is generally considered safe during pregnancy based on studies in patients with systemic lupus erythematosus and other rheumatic conditions, there may still be reluctance to institute this antimalarial during pregnancy for the sole purpose of antiviral therapy.
562. Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure: CASTLE-AF Trial.
作者: Christian Sohns.;Konstantin Zintl.;Yan Zhao.;Lilas Dagher.;Dietrich Andresen.;Jürgen Siebels.;Karl Wegscheider.;Susanne Sehner.;Lucas Boersma.;Béla Merkely.;Evgeny Pokushalov.;Prashanthan Sanders.;Heribert Schunkert.;Dietmar Bänsch.;Christian Mahnkopf.;Johannes Brachmann.;Nassir F Marrouche.
来源: Circ Arrhythm Electrophysiol. 2020年13卷10期e008461页
Recent data demonstrate promising effects on left ventricular dysfunction and left ventricular ejection fraction (LVEF) improvement following ablation for atrial fibrillation (AF) in patients with heart failure. We sought to study the relationship between LVEF, New York Heart Association class on presentation, and the end points of mortality and heart failure admissions in the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population. Furthermore, predictors for LVEF improvement were examined.
563. Power, Lesion Size Index and Oesophageal Temperature Alerts During Atrial Fibrillation Ablation: A Randomized Study.
作者: Milena Leo.;Michala Pedersen.;Kim Rajappan.;Matthew R Ginks.;Ross J Hunter.;Robert Bowers.;Manish Kalla.;Yaver Bashir.;Timothy R Betts.
来源: Circ Arrhythm Electrophysiol. 2020年13卷10期e008316页
Low radiofrequency powers are commonly used on the posterior wall of the left atrium for atrial fibrillation ablation to prevent esophageal damage. Compared with higher powers, they require longer ablation durations to achieve a target lesion size index (LSI). Esophageal heating during ablation is the result of a time-dependent process of conductive heating produced by nearby radiofrequency delivery. This randomized study was conducted to compare risk of esophageal heating and acute procedure success of different LSI-guided ablation protocols combining higher or lower radiofrequency power and different target LSI values.
564. Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial.
作者: Vibhu Parcha.;Nirav Patel.;Rajat Kalra.;Garima Arora.;James L Januzzi.;G Michael Felker.;Thomas J Wang.;Pankaj Arora.
来源: Circulation. 2020年142卷10期1018-1020页
NTproBNP ≤1000 has favorable prognostic implications in HF, but the prognosis is worse for Black patients at any level of achieved NTproBNP
565. Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
作者: Mark Y Chan.;Motakis Efthymios.;Sock Hwee Tan.;John W Pickering.;Richard Troughton.;Christopher Pemberton.;Hee-Hwa Ho.;Joseph-Francis Prabath.;Chester L Drum.;Lieng Hsi Ling.;Wern-Miin Soo.;Siang-Chew Chai.;Alan Fong.;Yen-Yee Oon.;Joshua P Loh.;Chi-Hang Lee.;Roger S Y Foo.;Matthew Andrew Ackers-Johnson.;Anna Pilbrow.;A Mark Richards.
来源: Circulation. 2020年142卷15期1408-1421页
Heart failure (HF) is the most common long-term complication of acute myocardial infarction (MI). Understanding plasma proteins associated with post-MI HF and their gene expression may identify new candidates for biomarker and drug target discovery.
566. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
作者: Kieran F Docherty.;Pardeep S Jhund.;Inder Anand.;Olof Bengtsson.;Michael Böhm.;Rudolf A de Boer.;David L DeMets.;Akshay S Desai.;Jaroslaw Drozdz.;Jonathan Howlett.;Silvio E Inzucchi.;Per Johanson.;Tzvetana Katova.;Lars Køber.;Mikhail N Kosiborod.;Anna Maria Langkilde.;Daniel Lindholm.;Felipe A Martinez.;Béla Merkely.;Jose C Nicolau.;Eileen O'Meara.;Piotr Ponikowski.;Marc S Sabatine.;Mikaela Sjöstrand.;Scott D Solomon.;Sergey Tereshchenko.;Subodh Verma.;John J V McMurray.
来源: Circulation. 2020年142卷17期1623-1632页
In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of dapagliflozin on these additional events.
567. Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock: Results From the CULPRIT-SHOCK Trial.
作者: Can Martin Sag.;Uwe Zeymer.;Taoufik Ouarrak.;Steffen Schneider.;Gilles Montalescot.;Kurt Huber.;Georg Fuernau.;Anne Freund.;Hans-Josef Feistritzer.;Steffen Desch.;Holger Thiele.;Lars S Maier.
来源: Circ Cardiovasc Interv. 2020年13卷9期e009562页
The management of patients with acute myocardial infarction complicated by cardiogenic shock is highly complex, and outcomes may depend on the time of hospital admission and subsequent intervention (ie, ON-hours versus OFF-hours). The CULPRIT-SHOCK trial (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) demonstrated superior outcome for culprit-lesion-only versus immediate multivessel percutaneous coronary intervention in patients presenting with acute myocardial infarction, multivessel disease, and cardiogenic shock. However, it is unknown whether the time of hospital admission affects the overall outcome of these high-risk patients.
568. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
作者: Natalie A Mordi.;Ify R Mordi.;Jagdeep S Singh.;Rory J McCrimmon.;Allan D Struthers.;Chim C Lang.
来源: Circulation. 2020年142卷18期1713-1724页
SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure-associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 inhibitors will likely be coprescribed with a loop diuretic, but this combined effect is not well-defined. Our aim was to assess the diuretic and natriuretic effect of empagliflozin in combination with loop diuretics.
569. Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy.
作者: Tjerk S J Opstal.;Renate M Hoogeveen.;Aernoud T L Fiolet.;Max J M Silvis.;Salem H K The.;Willem A Bax.;Dominique P V de Kleijn.;Arend Mosterd.;Erik S G Stroes.;Jan H Cornel.
来源: Circulation. 2020年142卷20期1996-1998页 570. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.
作者: Laura M Willemsen.;Paul W A Janssen.;Joyce Peper.;Mohamed A Soliman-Hamad.;Albert H M van Straten.;Patrick Klein.;Chris M Hackeng.;Uday Sonker.;Margreet W A Bekker.;Clemens von Birgelen.;Marc A Brouwer.;Pim van der Harst.;Eline A Vlot.;Vera H M Deneer.;Dean R P P Chan Pin Yin.;Marieke E Gimbel.;Kasper F Beukema.;Edgar J Daeter.;Johannes C Kelder.;Jan G P Tijssen.;Benno J W M Rensing.;Hendrik W van Es.;Martin J Swaans.;Jurrien M Ten Berg.
来源: Circulation. 2020年142卷19期1799-1807页
Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after coronary artery bypass graft surgery (CABG) despite aspirin use. The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG.
571. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
作者: Guillaume Marquis-Gravel.;Megan L Neely.;Marco Valgimigli.;Francesco Costa.;David Van Klaveren.;Rituparna Altner.;Deepak L Bhatt.;Paul W Armstrong.;Keith A A Fox.;Harvey D White.;E Magnus Ohman.;Matthew T Roe.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷9期e006582页
Longitudinal bleeding risk scores have been validated in patients treated with dual antiplatelet therapy (DAPT) following percutaneous coronary intervention. How these scores apply to the population of patients with acute coronary syndrome (ACS) treated without revascularization remains unknown. The objective was to evaluate and compare the performances of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) bleeding risk scores in the medically managed patients with ACS treated with DAPT.
572. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.
作者: David C Tong.;Stephen Quinn.;Arthur Nasis.;Chin Hiew.;Philip Roberts-Thomson.;Heath Adams.;Rumes Sriamareswaran.;Nay M Htun.;William Wilson.;Dion Stub.;William van Gaal.;Laurie Howes.;Nicholas Collins.;Andy Yong.;Ravinay Bhindi.;Robert Whitbourn.;Astin Lee.;Chris Hengel.;Kaleab Asrress.;Melanie Freeman.;John Amerena.;Andrew Wilson.;Jamie Layland.
来源: Circulation. 2020年142卷20期1890-1900页
Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS.
573. Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.
作者: Renato D Lopes.;Karen P Alexander.;Susanna R Stevens.;Harmony R Reynolds.;Gregg W Stone.;Ileana L Piña.;Frank W Rockhold.;Ahmed Elghamaz.;Jose Luis Lopez-Sendon.;Pedro S Farsky.;Alexander M Chernyavskiy.;Ariel Diaz.;Denis Phaneuf.;Mark A De Belder.;Yi-Tong Ma.;Luis A Guzman.;Michel Khouri.;Alessandro Sionis.;Derek J Hausenloy.;Rolf Doerr.;Joseph B Selvanayagam.;Aldo Pietro Maggioni.;Judith S Hochman.;David J Maron.
来源: Circulation. 2020年142卷18期1725-1735页
Whether an initial invasive strategy in patients with stable ischemic heart disease and at least moderate ischemia improves outcomes in the setting of a history of heart failure (HF) or left ventricular dysfunction (LVD) when ejection fraction is ≥35% but <45% is unknown.
574. Novel Panna Guide Wire Facilitates Percutaneous and Nonfluoroscopic Procedure for Atrial Septal Defect Closure: A Randomized Controlled Trial.
作者: Pengxu Kong.;Guangzhi Zhao.;Zonggang Zhang.;Weimin Zhang.;Taibing Fan.;Yu Han.;Kunjing Pang.;Shouzheng Wang.;Fengwen Zhang.;Weiwei Wang.;Shengshou Hu.;Xiangbin Pan.
来源: Circ Cardiovasc Interv. 2020年13卷9期e009281页
Echo-guided percutaneous procedures have been reported reliable and advantageous. However, the learning curve is difficult for junior doctors. We aimed to evaluate the safety and efficacy of a novel guidewire (Panna wire) in percutaneous atrial septal defect closure under transthoracic echocardiography guidance only.
575. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
作者: Finnian R Mc Causland.;Martin P Lefkowitz.;Brian Claggett.;Nagesh S Anavekar.;Michele Senni.;Mauro Gori.;Pardeep S Jhund.;Martina M McGrath.;Milton Packer.;Victor Shi.;Dirk J Van Veldhuisen.;Faiez Zannad.;Josep Comin-Colet.;Marc A Pfeffer.;John J V McMurray.;Scott D Solomon.
来源: Circulation. 2020年142卷13期1236-1245页
In patients with heart failure, chronic kidney disease is common and associated with a higher risk of renal events than in patients without chronic kidney disease. We assessed the renal effects of angiotensin/neprilysin inhibition in patients who have heart failure with preserved ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction).
576. Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention.
作者: Hironori Hara.;Kuniaki Takahashi.;Norihiro Kogame.;Mariusz Tomaniak.;Laura S M Kerkmeijer.;Masafumi Ono.;Hideyuki Kawashima.;Rutao Wang.;Chao Gao.;Joanna J Wykrzykowska.;Robbert J de Winter.;Franz-Josef Neumann.;Sylvain Plante.;Pedro Alves Lemos Neto.;Scot Garg.;Peter Jüni.;Pascal Vranckx.;Stephan Windecker.;Marco Valgimigli.;Christian Hamm.;Philippe Gabriel Steg.;Yoshinobu Onuma.;Patrick W Serruys.
来源: Circ Cardiovasc Interv. 2020年13卷9期e009177页
Bleeding and myocardial infarction (MI) after percutaneous coronary intervention are independent risk factors for mortality. This study aimed to investigate the association of all-cause mortality after percutaneous coronary intervention with site-reported bleeding and MI, when considered as individual, repeated, or combined events.
577. General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial.
作者: Holger Thiele.;Thomas Kurz.;Hans-Josef Feistritzer.;Georg Stachel.;Philipp Hartung.;Philipp Lurz.;Ingo Eitel.;Christoph Marquetand.;Holger Nef.;Oliver Doerr.;Ursula Vigelius-Rauch.;Alexander Lauten.;Ulf Landmesser.;Sascha Treskatsch.;Mohamed Abdel-Wahab.;Marcus Sandri.;David Holzhey.;Michael Borger.;Jörg Ender.;Hüseyin Ince.;Alper Öner.;Roza Meyer-Saraei.;Rainer Hambrecht.;Andreas Fach.;Thomas Augenstein.;Norbert Frey.;Inke R König.;Reinhard Vonthein.;Yvonne Rückert.;Anne-Kathrin Funkat.;Steffen Desch.;Astrid E Berggreen.;Matthias Heringlake.;Suzanne de Waha-Thiele.; .
来源: Circulation. 2020年142卷15期1437-1447页
In clinical practice, local anesthesia with conscious sedation (CS) is performed in roughly 50% of patients undergoing transcatheter aortic valve replacement. However, no randomized data assessing the safety and efficacy of CS versus general anesthesia (GA) are available.
578. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
作者: Giuseppe Gargiulo.;Giovanni Esposito.;Marisa Avvedimento.;Michael Nagler.;Pietro Minuz.;Gianluca Campo.;Felice Gragnano.;Negar Manavifar.;Raffaele Piccolo.;Matteo Tebaldi.;Plinio Cirillo.;Lukas Hunziker.;Pascal Vranckx.;Sergio Leonardi.;Dik Heg.;Stephan Windecker.;Marco Valgimigli.
来源: Circulation. 2020年142卷5期441-454页
Standard administration of newer oral P2Y12 inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to investigate the effects of cangrelor, tirofiban, and prasugrel, administered as chewed or integral loading dose, on IPA in patients undergoing primary percutaneous coronary intervention.
579. Exposure to Air Pollution and Particle Radioactivity With the Risk of Ventricular Arrhythmias.
作者: Adjani A Peralta.;Mark S Link.;Joel Schwartz.;Heike Luttmann-Gibson.;Douglas W Dockery.;Annelise Blomberg.;Yaguang Wei.;Murray A Mittleman.;Diane R Gold.;Francine Laden.;Brent A Coull.;Petros Koutrakis.
来源: Circulation. 2020年142卷9期858-867页
Individuals are exposed to air pollution and ionizing radiation from natural sources through inhalation of particles. This study investigates the association between cardiac arrhythmias and short-term exposures to fine particulate matter (particulate matter ≤2.5 µm aerodynamic diameter; PM2.5) and particle radioactivity.
580. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
作者: Marc P Bonaca.;Stephen D Wiviott.;Thomas A Zelniker.;Ofri Mosenzon.;Deepak L Bhatt.;Lawrence A Leiter.;Darren K McGuire.;Erica L Goodrich.;Remo Holanda De Mendonca Furtado.;John P H Wilding.;Avivit Cahn.;Ingrid A M Gause-Nilsson.;Per Johanson.;Martin Fredriksson.;Peter A Johansson.;Anna Maria Langkilde.;Itamar Raz.;Marc S Sabatine.
来源: Circulation. 2020年142卷8期734-747页
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular complications. The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk for hospitalization for heart failure (HHF) and kidney events in patients with type 2 diabetes mellitus. An increased risk of amputation has been observed with canagliflozin in 1 previous trial. We examined cardiovascular and kidney efficacy and the risk of limb-related events in patients with and without PAD in an exploratory analysis.
|